NCT05198960 2026-03-20
AVAJAK
University Hospital, Brest
Phase 3 Recruiting
Clinical Trials
17 trialsNCT07005024 2026-02-05
DOAC
University of Vermont
Phase 3 Recruiting
NCT02066454 2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3 Completed
NCT06580223 2025-07-18
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT05029063 2025-07-09
TRIM-Line
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT03045406 2025-06-24
CARAVAGGIO
Fadoi Foundation, Italy
Phase 3 Completed
NCT03090880 2022-11-17
PROVE
Assistance Publique - Hôpitaux de Paris
Phase 3 Terminated
NCT04999176 2021-08-10
VALERIA
Science Valley Research Institute
Phase 3 Unknown
NCT02583191 2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Phase 3 Terminated
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02935530 2019-05-14
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Huazhong University of Science and Technology
Phase 3 Completed
NCT03240120 2019-04-17
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
The University of Hong Kong
Phase 3 Unknown
NCT02746185 2018-08-13
CASTA-DIVA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT01448746 2017-02-07
Optimal Prophylactic Method of Venous Thromboembolism (VTE)
The Catholic University of Korea
Phase 3 Unknown
NCT00876915 2015-11-24
PHACS
University of Rochester
Phase 3 Terminated
NCT01164046 2014-12-03
Longheva
University Medical Center Groningen
Phase 3 Terminated
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed